The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
=== Cuban opposition === On 6 February, El País conducted interviews with various Cuban dissidents, including José Daniel Ferrer, Manuel Cuesta Morúa, and María Payá Acevedo. Their reactions were a mix of hope and warning against manipulations, including views that the Cuban government could cease talks when it stabilizes itself. On 22 May, Cuban opposition leader Ferrer claimed that there is no doubt that the communist regime will end by the end of 2026.
In the 1950s, shipping costs made up 33% of the price of oil transported from the Persian Gulf to the United States, but with the development of supertankers in the 1970s, the cost of shipping dropped to 5% of the price of Persian oil in the US. The share of the shipping cost on the final cost of the delivered commodity was less than 3% in 2010.
==== Member of the Order of the British Empire (MBE) ==== Civil Division Harcourt Thomas Bastian. For services to the economic development of the country. Fannie Suzanne Bethel, . For services to education and the community. Wilton Eric Darville. For services as a public officer and a trade unionist. Loretta Minnis. For services to education. Lamour Rolle. For community service to the Island of Bimini. Felix Nathaniel Stubbs. For services to the community, especially to youth.
The British South Africa Police (BSAP) was, for most of its existence, the police force of Southern Rhodesia and Rhodesia (now modern day Zimbabwe, since 1980). It was formed as a paramilitary force of mounted infantrymen in 1889 by Cecil Rhodes' British South Africa Company, from which it took its original name, the British South Africa Company's Police. Initially run directly by the company, it began to operate independently in 1896, at which time it also dropped "Company's" from its name. It thereafter served as Rhodesia's regular police force, retaining its name, until 1980, when it was superseded by the Zimbabwe Republic Police, soon after the country's reconstitution into Zimbabwe in April that year. While it was in the main a law enforcement organisation, the line between police and military was significantly blurred. BSAP officers trained both as policemen and regular soldiers until 1954. BSAP men served in the latter role during the First and Second World Wars, and also provided several support units to the Rhodesian Bush War of the 1960s and 1970s. During the Bush War, the BSAP operated several anti-guerrilla units, most prominently the Police Anti-Terrorist Unit, which tracked and engaged Communist guerrillas; the Support Unit, which was a police field force, nicknamed the "Black Boots" because of the colour of their footwear; and the Civilian African Tracking Unit, composed mostly of black Rhodesian trackers using traditional skills.
Sources: en.wikipedia.org
4 Li + 2 SOCl2 → 4 LiCl + 1⁄8 S8 + SO2 These non-rechargeable batteries have advantages over other forms of lithium batteries such as a high energy density, a wide operational temperature range, and long storage and operational lifespans. They are popular power sources for IoT devices such as asset trackers and utility meters as well as military and aircraft emergency beacons. However, their high cost, non-rechargeability, and safety concerns have limited their use in consumer devices. The contents of the batteries are very corrosive, the SO2 is toxic by inhalation, and the batteries therefore require special disposal procedures; additionally, they may explode if shorted. The technology was used on the 1997 Sojourner Mars rover.
These errors or mutations lead to the expression of a mutant huntingtin protein, which contains repetitive glutamine residues that are encoded by expanding CAG trinucleotide repeats in the gene. Huntington's disease is characterized by neuronal loss and gliosis. Symptoms of the disease include: movement disorder, cognitive decline, and behavioral disorder.
Pyruvate dehydrogenase complex (PDC) is a complex of three enzymes that converts pyruvate into acetyl-CoA by a process called pyruvate decarboxylation. Acetyl-CoA may then be used in the citric acid cycle to carry out cellular respiration, and this complex links the glycolysis metabolic pathway to the citric acid cycle. Pyruvate decarboxylation is also known as the "pyruvate dehydrogenase reaction" because it also involves the oxidation of pyruvate. The levels of pyruvate dehydrogenase enzymes play a major role in regulating the rate of carbohydrate metabolism and are strongly stimulated by the evolutionarily ancient hormone insulin. The PDC is opposed by the activity of pyruvate dehydrogenase kinase, and this mechanism plays a pivotal role in regulating rates of carbohydrate and lipid metabolism in many physiological states across taxa, including feeding, starvation, diabetes mellitus, hyperthyroidism, and hibernation. The multienzyme complex is structurally and functionally related to the oxoglutarate dehydrogenase complex (OGDC), the 2-oxoadipate dehydrogenase complex (OADHC) and the branched-chain oxo-acid dehydrogenase complex (BCKDC), all of which are members of the 2-oxoacid dehydrogenase complex family. A role for insulin in the regulation of glucose homeostasis, pyruvate dehydrogenase levels, and the generation of AMP-activated protein kinase (AMPK) in the electron transport chain has been evolutionarily conserved across species.
Like all parvoviruses, FPLV is extremely resistant to inactivation and can survive for longer than one year in a suitable environment. Kitten deaths have been reported in households of fully vaccinated cats, possibly because of exposure to large amounts of virus in the environment. In a recent study, microRNA responses to FPLV infection were identified in feline kidney cells by sequencing, providing a possible link between miRNA expression and pathogenesis of FPV infection. Infection occurs when the virus enters the body through the mouth or nose. Whether illness results or not depends on the immunity in the victim vs. the number of individual virus particles (i.e. the amount of virus) entering the body.
== College career == Bill Denehy, head coach of the University of Hartford, offered Bagwell a scholarship in spite of baseball not being his primary sport. Bagwell's acceptance of Hartford's baseball scholarship was based at least in part on the lack of a professional soccer league in the United States at the time. At Hartford, Denehy switched Bagwell to third base. Over three seasons playing for Hartford, he batted .413 in 400 at bats, a school record, and, for a time, a New England collegiate record. He also was the school's career home run (31) and run batted in (126) leader when he was drafted, and a two-time Eastern College Athletic Conference player of the year. In 1987 and 1988, he played collegiate summer baseball for the Chatham A's of the Cape Cod Baseball League, and in 1988 was named the starting third baseman for the East Division in the league's annual all-star game.
Sources: en.wikipedia.org
That Florey was not a pathologist was not overlooked; the Scottish pathologist Robert Muir declared: "There is no pathologist named Florey." The faculty board decided to take a chance on Florey, and he was appointed on 9 December. He took up the appointment in March 1932. The Floreys moved for the fourth time in five years, this time to a Victorian manor on 1 acre (0.40 ha) of ground about 1 mile (1.6 km) from the university, which later became student accommodation with the name "Florey Lodge". The chair came with a salary of £1,000 (equivalent to £57,000 in 2025) per annum, but there was no provision for an assistant. He took Kent with him anyway, eventually securing 50 shillings a week (equivalent to £141 in 2025) for him from the Medical Research Council (MRC). Guy's Hospital in London offered Florey a chair in pathology in February 1933. This caused alarm at the university, for it had recently lost two of its senior professors through the retirement of John Beresford Leathes and the departure of Edward Mellanby to become the secretary of the MRC. The university officials did not wish to lose Florey as well, and they raised his salary to £1,200 per annum to induce him to stay. The Sheffield Medical School was small, with only about fourteen students each year. The lack of a first-rate pathologist was remedied when Beatrice Pullinger joined the staff in January 1934, and she became Florey's ally in successfully lifting the standard of research and teaching in the department. While Florey's main interest was lysozyme, he pursued other lines of research as well.
Alza Corporation was an American pharmaceutical and medical systems company. Founded in 1968 by Dr. Alejandro Zaffaroni; the company's name is a portmanteau of his name. Alza was a major pioneer in the field of drug delivery systems, bringing over 20 prescription pharmaceutical products to market, and employing about 10,000 people during 20 years. In 2001, Alza was acquired by Johnson & Johnson via a stock-for-stock transaction worth US$10.5 billion. The company owns the patents on the following delivery platforms: Alzamer Depot D-Trans DUROS implant E-Trans electrotransport OROS (Osmotic Release Oral System) Macroflux transdermal system Stealth liposomal
Business biomimetics is the latest development in the application of biomimetics. Specifically it applies principles and practice from biological systems to business strategy, process, organization design, and strategic thinking. It has been successfully used by a range of industries in FMCG, defense, central government, packaging, and business services. Based on the work by Phil Richardson at the University of Bath the approach was launched at the House of Lords in May 2009. Generally, biometrics is used as a creativity technique that studies biological prototypes to get ideas for engineering solutions. In chemistry, a biomimetic synthesis is a chemical synthesis inspired by biochemical processes. Another, more recent meaning of the term bionics refers to merging organism and machine. This approach results in a hybrid system combining biological and engineering parts, which can also be referred as a cybernetic organism (cyborg). Practical realization of this was demonstrated in Kevin Warwick's implant experiments bringing about ultrasound input via his own nervous system.
This page discusses each of the main elements in the mixture of fission products produced by nuclear fission of the common nuclear fuels uranium and plutonium. The isotopes are listed by element, in order by atomic number. Neutron capture by the nuclear fuel in nuclear reactors and atomic bombs also produces actinides and transuranium elements (not listed here). These are found mixed with fission products in spent nuclear fuel and nuclear fallout. Neutron capture by materials of the nuclear reactor (shielding, cladding, etc.) or the environment (seawater, soil, etc.) produces activation products (not listed here). These are found in used nuclear reactors and nuclear fallout. A small but non-negligible proportion of fission events produces not two, but three fission products (not counting neutrons or subatomic particles). This ternary fission usually produces a very light nucleus such as helium (about 80% of ternary fissions produce an alpha particle) or hydrogen (most of the rest produce tritium or to a lesser extent deuterium and protium) as the third product. This is the main source of tritium from light water reactors. Another source of tritium is Helium-6 which immediately decays to (stable) Lithium-6. Lithium-6 produces tritium when hit by neutrons and is one of the main sources of commercially or militarily produced tritium. If the first or only step of nuclear reprocessing is an aqueous solution (as is the case in PUREX) this poses a problem as tritium contamination cannot be removed from water other than by costly isotope separation.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.